Barr set to launch generic Prozac in USA?
Barr Laboratories has announced plans to start selling a generic versionof Eli Lilly's antidepressant Prozac (fluoxetine) 20mg capsules by August 3, after this issue of the Marketletter went to press. The move follows a ruling by a US District Court judge on July 27, which found that Lilly's disputed patent on the drug ('2003) was invalid and lifted an injunction preventing Barr from marketing its generic. Another Prozac patent expires at midnight on August 2. Lilly said that it will continue to defend the '2003 patent's validity and aims to lodge an appeal with the US Supreme Court.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze